Abstract
This article describes the incidence of sexual dysfunction in 30 patients subjected to long-term treatment by paroxetine in dependence on the P 450 CYP 2D6 isoenzyme metabolic status. Measured on the Arizona Sexual Experience Scale (ASEX; McGahuey, Delgado, & Gelenberg, 1999), the incidence of sexual dysfunction in patients converted to CYP 2D6 poor metabolizers was markedly higher compared with patients who had no history of such conversion, a difference that reached the level of statistical significance. Our article discusses the incidence of sexual dysfunction in connection with reduced CYP 2D6 capacity.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antidepressive Agents, Second-Generation / administration & dosage
-
Antidepressive Agents, Second-Generation / adverse effects*
-
Antidepressive Agents, Second-Generation / pharmacokinetics
-
Cytochrome P-450 CYP2D6 / genetics
-
Cytochrome P-450 CYP2D6 / metabolism*
-
Czech Republic / epidemiology
-
Depressive Disorder / drug therapy*
-
Depressive Disorder / enzymology
-
Depressive Disorder / epidemiology
-
Female
-
Humans
-
Incidence
-
Libido / drug effects
-
Male
-
Middle Aged
-
Paroxetine / administration & dosage
-
Paroxetine / adverse effects*
-
Paroxetine / pharmacokinetics
-
Selective Serotonin Reuptake Inhibitors / administration & dosage
-
Selective Serotonin Reuptake Inhibitors / adverse effects*
-
Selective Serotonin Reuptake Inhibitors / pharmacokinetics
-
Sexual Dysfunctions, Psychological / chemically induced*
-
Sexual Dysfunctions, Psychological / diagnosis
-
Sexual Dysfunctions, Psychological / enzymology
-
Sexual Dysfunctions, Psychological / epidemiology
Substances
-
Antidepressive Agents, Second-Generation
-
Serotonin Uptake Inhibitors
-
Paroxetine
-
Cytochrome P-450 CYP2D6